Search
Results: 1
A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson's Disease in Participants With Leucine-Rich Repeat Kinase 2 Mutation.
Malidi Ahamadi, Nitin Mehrotra, Nathan Hanan, Ka Lai Yee, Ferdous Gheyas, Judith Anton, Massimo Bani, Babak Boroojerdi, Hans Smit, Jonas Weidemann, Sreeraj Macha, Vincent Thuillier, Chao Chen, Minhua Yang, Caroline H Williams-Gray, Glenn T Stebbins, Gennaro Pagano, Yaming Hang, Kenneth Marek, Charles S Venuto, Monica Javidnia, David Dexter, Anne Pedata, Bob Stafford, Mussie Akalu, Diane Stephenson, Klaus Romero, Vikram Sinha, Critical Path for Parkinson’s Consortium
Mar 19, 2021
Leucine-rich repeat kinase 2 (LRRK2) inhibitors are currently in clinical development as interventions to slow progression of Parkinson's disease (PD). Understanding the rate of progression in PD as measured by both motor and...
Adult Age Factors Aged Aged 80 and over Antiparkinson Agents Databases Factual Disease Progression Female Glucosylceramidase Heterozygote Humans Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Longitudinal Studies Male Middle Aged Models Theoretical Mutation Parkinson Disease Predictive Value of Tests Severity of Illness Index ALPHA-SYNUCLEIN